|
rs712829
|
EGFR;LOC105375284
|
Adenocarcinoma of lung (disorder)
|
|
0.010 |
GeneticVariation |
BEFREE |
When patients were stratified according to the lung cancer type, a significant association was detected between both rs712829 and rs2072454 and adenocarcinoma lung cancer (<i>p</i> < 0.05).
|
30011810 |
2018 |
|
rs1554350382
|
EGFR;EGFR-AS1
|
Adenocarcinoma of lung (disorder)
|
AGTC |
0.700 |
GeneticVariation |
CLINVAR |
|
|
|
|
rs121434569
|
EGFR;EGFR-AS1
|
Adenocarcinoma of lung (disorder)
|
|
0.100 |
GeneticVariation |
BEFREE |
Herein, we report the first case of a patient with EGFR-mutant lung adenocarcinoma with a long-lasting response to first-line erlotinib treatment who acquired resistance to treatment because of acquisition of both EGFR-T790M mutation and "high-grade" large cell neuroendocrine transformation.
|
28778263 |
2017 |
|
rs121434569
|
EGFR;EGFR-AS1
|
Adenocarcinoma of lung (disorder)
|
|
0.100 |
GeneticVariation |
BEFREE |
This study aimed to assess the total cost of care of a urine-testing strategy (UTS) versus a tissue-testing strategy (TTS) for T790M detection, in patients with EGFR-mutation positive lung adenocarcinoma and progression on prior TKI therapy.
|
28676213 |
2017 |
|
rs121434569
|
EGFR;EGFR-AS1
|
Adenocarcinoma of lung (disorder)
|
|
0.100 |
GeneticVariation |
BEFREE |
The authors report two cases of epidermal growth factor receptor gene (EGFR)-mutant stage IV lung adenocarcinomas developing immunohistochemically proven squamous cell carcinoma (SCC) "transformation" concurrently with T790M EGFR mutation, leading to acquired resistance to EGFR inhibitors.
|
26746366 |
2016 |
|
rs121434569
|
EGFR;EGFR-AS1
|
Adenocarcinoma of lung (disorder)
|
|
0.100 |
GeneticVariation |
BEFREE |
Sustained response to standard dose osimertinib in a patient with plasma T790M-positive leptomeningeal metastases from primary lung adenocarcinoma.
|
28296233 |
2017 |
|
rs121434569
|
EGFR;EGFR-AS1
|
Adenocarcinoma of lung (disorder)
|
|
0.100 |
GeneticVariation |
BEFREE |
Effects of vandetanib on lung adenocarcinoma cells harboring epidermal growth factor receptor T790M mutation in vivo.
|
19491268 |
2009 |
|
rs121434569
|
EGFR;EGFR-AS1
|
Adenocarcinoma of lung (disorder)
|
|
0.100 |
GeneticVariation |
BEFREE |
<i>EGFR</i> T790M detection rate in lung adenocarcinomas at baseline using droplet digital PCR and validation by ultra-deep next generation sequencing.
|
31737495 |
2019 |
|
rs121434569
|
EGFR;EGFR-AS1
|
Adenocarcinoma of lung (disorder)
|
|
0.100 |
GeneticVariation |
BEFREE |
It suggests that T790M is possibly significant not only for EGFR TKI resistance but also the progression in lung adenocarcinoma.
|
29887244 |
2018 |
|
rs121434569
|
EGFR;EGFR-AS1
|
Adenocarcinoma of lung (disorder)
|
|
0.100 |
GeneticVariation |
BEFREE |
Mutational monitoring of EGFR T790M in cfDNA for clinical outcome prediction in EGFR-mutant lung adenocarcinoma.
|
30444875 |
2018 |
|
rs121434569
|
EGFR;EGFR-AS1
|
Adenocarcinoma of lung (disorder)
|
|
0.100 |
GeneticVariation |
BEFREE |
Although next-generation sequencing (NGS) is a robust technology for comprehensive assessment of EGFR-mutant lung adenocarcinomas with acquired resistance to tyrosine kinase inhibitors, it may not provide sufficiently rapid and sensitive detection of the EGFR T790M mutation, the most clinically relevant resistance biomarker.
|
27631691 |
2016 |
|
rs121434569
|
EGFR;EGFR-AS1
|
Adenocarcinoma of lung (disorder)
|
|
0.100 |
GeneticVariation |
BEFREE |
These observations unveiled the significance of YAP1 in EGFR mutant lung adenocarcinomas and identified YAP1 as a promising therapeutic target for EGFR-dependent lung adenocarcinoma patients, including those with EGFR T790M-caused TKI resistance.
|
29163769 |
2017 |
|
rs121434569
|
EGFR;EGFR-AS1
|
Adenocarcinoma of lung (disorder)
|
|
0.100 |
GeneticVariation |
BEFREE |
Our report demonstrates that osimertinib is able to inhibit the growth of a radiotherapy- and surgery-refractory EGFR T790M-positive brain metastasis in a patient with lung adenocarcinoma.
|
27486808 |
2016 |
|
rs121434569
|
EGFR;EGFR-AS1
|
Adenocarcinoma of lung (disorder)
|
|
0.100 |
GeneticVariation |
BEFREE |
Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors.
|
17085664 |
2006 |
|
rs121434569
|
EGFR;EGFR-AS1
|
Adenocarcinoma of lung (disorder)
|
|
0.100 |
GeneticVariation |
BEFREE |
Plasma samples from patients with advanced EGFR-mutated lung adenocarcinoma were analyzed for EGFR T790M, exon 19 deletions, and L858R mutations by both ddPCR and Cobas.
|
30810887 |
2019 |
|
rs121434569
|
EGFR;EGFR-AS1
|
Adenocarcinoma of lung (disorder)
|
|
0.100 |
GeneticVariation |
BEFREE |
EGFR T790M mutation and cMET amplification are main mechanisms leading to EGFR TKI resistance in lung adenocarcinoma.
|
29616327 |
2018 |
|
rs121434569
|
EGFR;EGFR-AS1
|
Adenocarcinoma of lung (disorder)
|
|
0.100 |
GeneticVariation |
BEFREE |
Concurrent epidermal growth factor receptor T790M secondary mutation and epithelial-mesenchymal transition in a lung adenocarcinoma patient with EGFR-TKI drug resistance.
|
28786540 |
2017 |
|
rs121434569
|
EGFR;EGFR-AS1
|
Adenocarcinoma of lung (disorder)
|
|
0.100 |
GeneticVariation |
BEFREE |
Origin of the T790M mutation and its impact on the clinical outcomes of patients with lung adenocarcinoma receiving EGFR-TKIs.
|
30760406 |
2019 |
|
rs121434569
|
EGFR;EGFR-AS1
|
Adenocarcinoma of lung (disorder)
|
|
0.100 |
GeneticVariation |
BEFREE |
After her death, an autopsy revealed SCLC transformation and EGFR T790M secondary mutation (T790M) as mutually exclusive resistance mechanisms occurring differently in different metastases; two liver metastases (SCLC versus AC with T790M) and two lymph node metastases (SCLC versus AC with T790M) were analyzed to compare the expression status of immune markers by immunohistochemistry and by an immune oncology gene expression panel.
|
28193529 |
2017 |
|
rs121434569
|
EGFR;EGFR-AS1
|
Adenocarcinoma of lung (disorder)
|
|
0.100 |
GeneticVariation |
BEFREE |
EGFR-mutation lung adenocarcinoma cell lines PC9 and the gefitinib-resistant with T790M Mutation cell lines PC9/GR were chosen as cell models, and PC9/GR were treated with 5-aza-CdR (1 μmol/L).
|
26722491 |
2015 |
|
rs121434569
|
EGFR;EGFR-AS1
|
Adenocarcinoma of lung (disorder)
|
|
0.100 |
GeneticVariation |
BEFREE |
The Association of Acquired T790M Mutation with Clinical Characteristics after Resistance to First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Lung Adenocarcinoma.
|
29334606 |
2018 |
|
rs121434569
|
EGFR;EGFR-AS1
|
Adenocarcinoma of lung (disorder)
|
|
0.100 |
GeneticVariation |
BEFREE |
Among them, 41 patients with <i>EGFR</i>-mutant lung adenocarcinoma and EGFR-TKI progression were selected for an investigation of T790M mutation prevalence at rebiopsy.
|
29581791 |
2018 |
|
rs121434569
|
EGFR;EGFR-AS1
|
Adenocarcinoma of lung (disorder)
|
|
0.100 |
GeneticVariation |
BEFREE |
Statistical analyses were performed to examine the associations between clinicopathologic features of lung adenocarcinoma and presence of acquired T790M mutation.
|
29858020 |
2018 |
|
rs121434569
|
EGFR;EGFR-AS1
|
Adenocarcinoma of lung (disorder)
|
|
0.100 |
GeneticVariation |
BEFREE |
We used a competitive allele-specific polymerase chain reaction (CAST-PCR) to analyze the incidence and clinical significance of T790M mutations in 153 lung adenocarcinomas with EGFR-activating mutations.
|
28932544 |
2017 |
|
rs121434569
|
EGFR;EGFR-AS1
|
Adenocarcinoma of lung (disorder)
|
|
0.100 |
GeneticVariation |
BEFREE |
Squamous cell transformation and <i>EGFR</i> T790M mutation as acquired resistance mechanisms in a patient with lung adenocarcinoma treated with a tyrosine kinase inhibitor: A case report.
|
29113230 |
2017 |